Table of Contents Table of Contents
Previous Page  57 / 114 Next Page
Information
Show Menu
Previous Page 57 / 114 Next Page
Page Background

53

NCCN Guidelines for Patients

®

Breast Cancer - Early-Stage

(STAGES I AND II)

, Version 1.2016

4

Chemotherapy and HER2 inhibitors Regimens: HER-2 positive cancer

Chart 4.7 Other regimens*

Other Regimen

Schedule

Total time

AC

Four 21-day cycles

1 year and 3 months

then docetaxel

Four 21-day cycles

with pertuzumab

On day 1 during docetaxel cycles

and trastuzumab

On day 1 during docetaxel cycles then every

21 days to complete 1 year

Docetaxel + cyclophosphamide Four 21-day cycles

1 year

with trastuzumab

Weekly during docetaxel cycles then every 21

days to complete 1 year

FEC

Three 21-day cycles

1 year and 9 weeks

then docetaxel

Three 21-day cycles

with pertuzumab

On day 1 during docetaxel cycles

and trastuzumab

On day 1 during docetaxel cycles then every

21 days to complete 1 year

FEC

Three 21-day cycles

1 year and 9 weeks

then paclitaxel

Three 21-day cycles

with pertuzumab

On day 1 during paclitaxel cycles

and trastuzumab

On day 1 during paclitaxel cycles then every

21 days to complete 1 year

Paclitaxel

Twelve 7-day cycles

1 year

with trastuzumab

Weekly during paclitaxel then every 7 or 21

days to complete 1 year

Neoadjuvant docetaxel

Four 21-day cycles

3 months

with trastuzumab and

pertuzumab, and

On day 1 during docetaxel cycles

Adjuvant FEC

Three 21-day cycles

1 year and 9 weeks

then trastuzumab

Every 21 days to complete 1 year

Neoadjuvant paclitaxel

Four 21-day cycles

3 months

with trastuzumab and

pertuzumab, and

On day 1 during docetaxel cycles

Adjuvant FEC

Three 21-day cycles

1 year and 9 weeks

then trastuzumab

Every 21 days to complete 1 year

*Preferred and other regimens are based on how well they work, side effects, and treatment schedules.

Continued from previous page

.